Enlivex Therapeutics Ltd.
ENLV · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | $25 | $27 | $21 | $26 |
| - Cash | $4 | $2 | $2 | $3 |
| + Debt | $1 | $0 | $1 | $1 |
| Enterprise Value | $22 | $25 | $20 | $23 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Gross Profit | -$0 | -$0 | -$0 | -$0 |
| % Margin | – | – | – | – |
| EBITDA | -$2 | -$3 | -$3 | -$5 |
| % Margin | – | – | – | – |
| Net Income | -$2 | -$2 | -$3 | -$5 |
| % Margin | – | – | – | – |
| EPS Diluted | -0.092 | -0.078 | -0.16 | -0.24 |
| % Growth | -17.1% | 51.1% | 33.3% | – |
| Operating Cash Flow | -$2 | -$1 | -$5 | -$4 |
| Capital Expenditures | -$0 | -$0 | -$0 | -$0 |
| Free Cash Flow | -$2 | -$1 | -$5 | -$4 |